ZA917170B - Novel antibodies for treatment and prevention of infection in animals and man - Google Patents

Novel antibodies for treatment and prevention of infection in animals and man

Info

Publication number
ZA917170B
ZA917170B ZA917170A ZA917170A ZA917170B ZA 917170 B ZA917170 B ZA 917170B ZA 917170 A ZA917170 A ZA 917170A ZA 917170 A ZA917170 A ZA 917170A ZA 917170 B ZA917170 B ZA 917170B
Authority
ZA
South Africa
Prior art keywords
infection
man
animals
prevention
treatment
Prior art date
Application number
ZA917170A
Inventor
William J Harris
J Harris William
Philip R Tempest
R Tempest Philip
Geraldine Taylor
Taylor Geraldine
Original Assignee
Scotgen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scotgen Ltd filed Critical Scotgen Ltd
Publication of ZA917170B publication Critical patent/ZA917170B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
ZA917170A 1990-09-11 1991-09-10 Novel antibodies for treatment and prevention of infection in animals and man ZA917170B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909019812A GB9019812D0 (en) 1990-09-11 1990-09-11 Novel antibodies for treatment and prevention of infection in animals and man

Publications (1)

Publication Number Publication Date
ZA917170B true ZA917170B (en) 1992-07-29

Family

ID=10682003

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA917170A ZA917170B (en) 1990-09-11 1991-09-10 Novel antibodies for treatment and prevention of infection in animals and man

Country Status (12)

Country Link
EP (1) EP0548190A1 (en)
JP (1) JPH06501152A (en)
KR (1) KR930702519A (en)
AU (1) AU654827B2 (en)
CA (1) CA2091335A1 (en)
GB (1) GB9019812D0 (en)
IE (1) IE913177A1 (en)
MX (1) MX9101046A (en)
NZ (1) NZ239728A (en)
PT (1) PT98944B (en)
WO (1) WO1992004381A1 (en)
ZA (1) ZA917170B (en)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US6750325B1 (en) 1989-12-21 2004-06-15 Celltech R&D Limited CD3 specific recombinant antibody
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
DE69130708T2 (en) * 1990-07-19 1999-05-27 Us Commerce IMPROVED IMMUNOTHERAPEUTIC METHOD FOR PREVENTING OR TREATING VIRAL DISEASES OF THE respiratory tract
US5994510A (en) * 1990-12-21 1999-11-30 Celltech Therapeutics Limited Recombinant antibodies specific for TNFα
IE921169A1 (en) 1991-04-10 1992-10-21 Scripps Research Inst Heterodimeric receptor libraries using phagemids
LU91067I2 (en) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab and its variants and immunochemical derivatives including immotoxins
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
US5824307A (en) * 1991-12-23 1998-10-20 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
US5646253A (en) * 1994-03-08 1997-07-08 Memorial Sloan-Kettering Cancer Center Recombinant human anti-LK26 antibodies
GB9207479D0 (en) * 1992-04-06 1992-05-20 Scotgen Ltd Novel antibodies for treatment and prevention of respiratory syncytial virus infection in animals and man
US6685942B1 (en) 1993-12-10 2004-02-03 The Scripps Research Institute Human neutralizing monoclonal antibodies to respiratory syncytial virus
WO1994006448A1 (en) * 1992-09-16 1994-03-31 The Scripps Research Institute Human neutralizing monoclonal antibodies to respiratory syncytial virus
JPH08507680A (en) 1993-01-12 1996-08-20 バイオジェン インコーポレイテッド Recombinant anti-VLA4 antibody molecule
WO1995004081A1 (en) * 1993-07-30 1995-02-09 Oravax, Inc. MONOCLONAL IgA ANTIBODY AGAINST RESPIRATORY SYNCYTIAL VIRUS
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
US6310185B1 (en) * 1994-03-08 2001-10-30 Memorial Sloan Kettering Cancer Center Recombinant human anti-Lewis Y antibodies
WO1995031546A1 (en) * 1994-04-28 1995-11-23 Scotgen Biopharmaceuticals, Inc. Recombinant human anti-varicella zoster virus antibodies
WO1997011177A1 (en) 1995-09-18 1997-03-27 Intracel Corporation Neutralizing monoclonal antibodies to respiratory syncytial virus
CA2257357C (en) 1996-06-07 2010-04-13 Neorx Corporation Humanized antibodies with modified glycosylation
DE69839765D1 (en) 1997-01-27 2008-09-04 Ludwig Inst Cancer Res LOCATION-1 TUMOR ASSOCIATED NUCLEIC ACIDS
ATE530180T1 (en) 1997-04-02 2011-11-15 Brigham & Womens Hospital METHOD FOR DETERMINING THE INDIVIDUAL RISK PROFILES OF ATHEROSCLEROTIC DISEASES
US6160099A (en) * 1998-11-24 2000-12-12 Jonak; Zdenka Ludmila Anti-human αv β3 and αv β5 antibodies
JP2002536966A (en) 1998-12-30 2002-11-05 ベス・イスラエル・ディーコニス・メディカル・センター・インコーポレーテッド Characterization of the calcium channel family
US7166573B1 (en) 1999-05-28 2007-01-23 Ludwig Institute For Cancer Research Breast, gastric and prostate cancer associated antigens and uses therefor
AU5632500A (en) 1999-06-30 2001-01-31 Ludwig Institute For Cancer Research Cancer associated antigens and uses therefor
PT1207905E (en) 1999-09-03 2010-12-07 Brigham & Womens Hospital Methods and compositions for treatment of inflammatory disease using cadherin-11 modulating agents
KR20020047249A (en) 1999-10-19 2002-06-21 에드워드 에이. 맥더모트, 주니어 MAGE-A12 Antigenic Peptides and Uses Thereof
HUP0300219A3 (en) * 1999-12-23 2005-07-28 Icn Pharmaceuticals Inc Costa Compositions and methods for l-nucleosides, l-nucleotides, and their analogs
DE10211088A1 (en) 2002-03-13 2003-09-25 Ugur Sahin Gene products differentially expressed in tumors and their use
HUE039881T2 (en) 2002-05-09 2019-02-28 Brigham & Womens Hospital Inc 1l1rl-1 as a cardiovascular disease marker
DE10254601A1 (en) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Gene products differentially expressed in tumors and their use
MXPA05008533A (en) 2003-02-11 2005-10-20 Transkaryotic Therapies Inc Diagnosis and treatment of multiple sulfatase deficiency and other using a formylglycine generating enzyme (fge).
EP2384753B1 (en) 2003-08-29 2016-01-06 The Brigham and Women's Hospital, Inc. Hydantoin derivatives as inhibitors of cellular necrosis
DE10341812A1 (en) 2003-09-10 2005-04-07 Ganymed Pharmaceuticals Ag Differentially expressed in tumors gene products and their use
DE10344799A1 (en) 2003-09-26 2005-04-14 Ganymed Pharmaceuticals Ag Identification of surface-associated antigens for tumor diagnosis and therapy
DE102004023187A1 (en) 2004-05-11 2005-12-01 Ganymed Pharmaceuticals Ag Identification of surface-associated antigens for tumor diagnosis and therapy
DE102004024617A1 (en) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentially expressed in tumors gene products and their use
CA2624601C (en) 2004-10-06 2018-07-03 The Brigham And Women's Hospital, Inc. Relevance of achieved levels of markers of systemic inflammation following treatment
DE102005013846A1 (en) 2005-03-24 2006-10-05 Ganymed Pharmaceuticals Ag Identification of surface-associated antigens for tumor diagnosis and therapy
EP1762575A1 (en) 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identification of tumor-associated antigens for diagnosis and therapy
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
EP1795596A1 (en) 2005-12-08 2007-06-13 Ganymed Pharmaceuticals AG Composition and methods for therapy and diagnosis of cancer
DE102005059242A1 (en) 2005-12-12 2007-06-14 Johannes Gutenberg-Universität Mainz, Vertreten Durch Den Präsidenten Molecular markers for tumor diagnosis and therapy
CA2649148C (en) 2006-04-13 2016-08-23 Chugai Seiyaku Kabushiki Kaisha Taurine transporter gene
EP1911851A1 (en) 2006-10-12 2008-04-16 Ganymed Pharmaceuticals AG Compositions and methods for therapy and diagnosis of cancer and cancer metastasis
WO2008103845A2 (en) 2007-02-23 2008-08-28 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services. Monoclonal antibodies that neutralize anthrax toxins
EP2135946B1 (en) 2007-03-15 2015-12-09 Chugai Seiyaku Kabushiki Kaisha Method for production of polypeptide
ES2591284T3 (en) 2007-08-07 2016-11-25 Chugai Seiyaku Kabushiki Kaisha Method for the production of heterogeneous proteins
EP2194126B1 (en) 2007-10-15 2014-01-15 Chugai Seiyaku Kabushiki Kaisha Method of constructing cells with high productivity of foreign protein
EP2060583A1 (en) 2007-10-23 2009-05-20 Ganymed Pharmaceuticals AG Identification of tumor-associated markers for diagnosis and therapy
JP5337044B2 (en) * 2007-10-24 2013-11-06 中外製薬株式会社 Cell for production of heterologous protein and production method using the same
EP2108701A1 (en) 2008-04-10 2009-10-14 Ganymed Pharmaceuticals AG Methods involving MS4A12 and agents targeting MS4A12 for therapy, diagnosis and testing
KR20110033233A (en) * 2008-07-21 2011-03-30 이뮤노메딕스, 인코오포레이티드 Structural variants of antibodies for improved therapeutic characteristics
EP2221063A1 (en) 2009-02-20 2010-08-25 Ganymed Pharmaceuticals AG Methods and compositions for diagnosis and treatment of cancer
HRP20231525T1 (en) 2009-02-20 2024-03-15 Astellas Pharma Inc. Methods and compositions for diagnosis and treatment of cancer
EP2221375A1 (en) 2009-02-20 2010-08-25 Ganymed Pharmaceuticals AG Methods and compositions for diagnosis and treatment of cancer
JP5715050B2 (en) 2009-04-22 2015-05-07 中外製薬株式会社 Method for producing cells producing high production of heterologous protein
EP2249159A1 (en) 2009-04-29 2010-11-10 Ganymed Pharmaceuticals AG Identification of tumor-associated markers for diagnosis and therapy
EP3689911A1 (en) 2009-11-11 2020-08-05 Ganymed Pharmaceuticals GmbH Antibodies specific for claudin 6 (cldn6)
DK3466977T3 (en) 2010-04-16 2022-04-11 Biogen Ma Inc Anti-vla-4-antistoffer
WO2011133894A2 (en) 2010-04-23 2011-10-27 Purdue Research Foundation Protein drug formulations and packages
EP3138915A1 (en) 2010-05-04 2017-03-08 The Brigham and Women's Hospital, Inc. Detection and treatment of fibrosis
EP2404936A1 (en) 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Cancer therapy using CLDN6 target-directed antibodies in vivo
RS58087B1 (en) 2011-05-13 2019-02-28 Ganymed Pharmaceuticals Gmbh Antibodies for treatment of cancer expressing claudin 6
WO2013078122A1 (en) 2011-11-22 2013-05-30 President And Fellows Of Harvard College Diabetes diagnosis through the detection of glycated proteins in urine
WO2013167153A1 (en) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
JP2016514693A (en) 2013-03-15 2016-05-23 プレジデント アンド フェローズ オブ ハーバード カレッジ Hybrid necrotosis inhibitor
WO2015014376A1 (en) 2013-07-31 2015-02-05 Biontech Ag Diagnosis and therapy of cancer involving cancer stem cells
KR20160127736A (en) 2014-01-24 2016-11-04 더 헨리 엠. 잭슨 파운데이션 포 더 어드벤스먼트 오브 밀리터리 메디신, 인코포레이티드 Antibodies against f glycoprotein of hendra and nipah viruses
WO2016062323A1 (en) 2014-10-20 2016-04-28 Biontech Ag Methods and compositions for diagnosis and treatment of cancer
JO3555B1 (en) 2015-10-29 2020-07-05 Merck Sharp & Dohme Antibody neutralizing human respiratory syncytial virus
WO2017147258A1 (en) 2016-02-23 2017-08-31 Indiana University Research & Technology Corporation Emapii neutralizing antibody limits influenza a virus (iav)-induced lung injury
WO2017213695A1 (en) 2016-06-07 2017-12-14 The Brigham And Women's Hospital, Inc. Compositions and methods relating to t peripheral helper cells in autoantibody-associated conditions
JP6889328B2 (en) 2017-07-31 2021-06-18 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Humanization method based on three-dimensional structure

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4800078A (en) * 1987-05-28 1989-01-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Immunotherapeutic method of treating respiratory disease by intranasal administration of Igb

Also Published As

Publication number Publication date
NZ239728A (en) 1995-07-26
PT98944B (en) 1999-02-26
PT98944A (en) 1992-08-31
CA2091335A1 (en) 1992-03-12
AU8505891A (en) 1992-03-30
MX9101046A (en) 1992-05-04
WO1992004381A1 (en) 1992-03-19
JPH06501152A (en) 1994-02-10
EP0548190A1 (en) 1993-06-30
GB9019812D0 (en) 1990-10-24
KR930702519A (en) 1993-09-09
IE913177A1 (en) 1992-03-11
AU654827B2 (en) 1994-11-24

Similar Documents

Publication Publication Date Title
ZA917170B (en) Novel antibodies for treatment and prevention of infection in animals and man
ZA932445B (en) Novel antibodies for treatment and prevention of respiratory syncytial virus infection in animals and man
SG49658A1 (en) Treatment of condition and disease
GB9203206D0 (en) Treatment of particulate material
GB9014307D0 (en) Method of treatment and compositions therefor
ZA914435B (en) Treatment of disease
FR2663230B1 (en) HYGIENE AND TREATMENT DEVICE.
GB2263905B (en) Treatment of waste animal materials
EP0527771A4 (en) Polypeptides useful in diagnosis of and treatment against mycoplasma infections in animals
EP0540575A4 (en) Human meg-csf protein and methods
ZA923125B (en) Treatment of mastitis
CS61691A2 (en) Composition for dung-water treatment and method of dung-water treatment
KR960006863B1 (en) Pharmaceutical preparation for treatment of mastitis in animals and humans
EG20171A (en) Treatment of conditions and disease
ZA914464B (en) Method and compositions for treating hiv-type 1 infection
GB9216360D0 (en) Treatment of blood
GB2245475B (en) Improvements in the treatment of animal feeds
RU1833740C (en) Way of treatment and prophylaxis of allergic diseases of reagent type
GB9021960D0 (en) Treatment of flax
RU1785692C (en) Preparation for treatment and prophylaxis piglets colibacteriosis
RU1833739C (en) Way of treatment hyperekaliemia
ZA903993B (en) Treatment of animals
LTIP472A (en) Composition for the treatment of infection and disease caused by hepatit b virus
NZ233973A (en) Treatment of viral and/or bacterial infections
NZ231322A (en) Treatment of viral and/or bacterial infections